Results 21 to 30 of about 9,342,565 (376)

Hematologic manifestations of celiac disease

Blood, 2006
AbstractCeliac disease is a common systemic disorder that can have multiple hematologic manifestations. Patients with celiac disease may present to hematologists for evaluation of various hematologic problems prior to receiving a diagnosis of celiac disease.
Þorvarður R. Hálfdánarson, Mark R. Litzow, Joseph A. Murray   +2 more
openalex   +5 more sources

Hematologic Disease and Heart Disease

, 2007
Severe anemia is an important problem in patients with underlying coronary heart disease because further reduction in oxygen delivery to myocardium supplied by stenotic coronary arteries may lead to angina or myocardial infarction. Cautious transfusion may be critically important acutely in the patient with an acute coronary syndrome ...
Martin D. Phillips, James T. Willerson
openalex   +3 more sources

Salient features of hematological diseases [PDF]

Annals of Oncology, 2007
M.F. Fey
openalex   +6 more sources

Hematological Diseases and Osteoporosis [PDF]

International Journal of Molecular Sciences, 2020
Secondary osteoporosis is a common clinical problem faced by bone specialists, with a higher frequency in men than in women. One of several causes of secondary osteoporosis is hematological disease. There are numerous hematological diseases that can have a deleterious impact on bone health.
Gaudio A., Xourafa A., Rapisarda R., Zanoli L., Signorelli S. S., Castellino P.   +5 more
openaire   +3 more sources

Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.

Blood, 2021
Complement is an elaborate system of the innate immunity. Genetic variants and autoantibodies leading to excessive complement activation are implicated in a variety of human diseases.
E. Gavriilaki, R. Peffault de Latour, A. Risitano   +2 more
semanticscholar   +1 more source

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

Blood Cancer Journal, 2023
CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR T-cell therapies have been developed to reduce the possibility of CD19 ...
Sining Liu, Xinyue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Shengli Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, Depei Wu, Qingya Cui, Xiaowen Tang   +21 more
doaj   +1 more source

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

Experimental Hematology & Oncology, 2022
Relapsed/refractory acute myeloid leukemia (AML) patients generally have a dismal prognosis and the treatment remains challenging. Due to the expression of CD7 on 30% AML and not on normal myeloid and erythroid cells, CD7 is an attractive target for ...
Xuanqi Cao, Haiping Dai, Qingya Cui, Zheng Li, Wenhong Shen, Jinlan Pan, Hongjie Shen, Qinfen Ma, Mengyun Li, Sifan Chen, Juncheng Chen, Xiaming Zhu, Huimin Meng, Lin Yang, Depei Wu, Xiaowen Tang   +15 more
doaj   +1 more source

Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia

Clinical Epigenetics, 2023
Background DNA methylation is a form of epigenetic modification that regulates gene expression. However, there are limited data on the comprehensive analysis of DNA methylation regulated gene mutations (DMRGM) in acute myeloid leukemia (AML) mainly ...
Xiaoyan Xu, Hong Wang, Haohao Han, Yifang Yao, Xueqian Li, Jiaqian Qi, Chengsen Cai, Meng Zhou, Yaqiong Tang, Tingting Pan, Ziyan Zhang, Jingyi Yang, Depei Wu, Yue Han   +13 more
doaj   +1 more source

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients

Experimental Hematology & Oncology, 2023
Relapse is a major limitation of chimeric antigen receptor (CAR) T-cell therapy. Here, we speculated that decitabine (DAC) in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen may improve the efficacy of CD19/CD22 CAR T ...
Yunju Ma, Haiping Dai, Qingya Cui, Sining Liu, Liqing Kang, Xiaying Lian, Wei Cui, Jia Yin, Lingling Liu, Mengjie Cai, Lei Yu, Depei Wu, Xiaowen Tang   +12 more
doaj   +1 more source

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. [PDF]

, 2020
ObjectiveTo evaluate the frequency of cell-bound complement activation products (CB-CAPs) as a marker of complement activation in patients with suspected systemic lupus erythematosus (SLE) and the usefulness of this biomarker as a predictor of the ...
Alexander, Roberta Vezza, Arriens, Cristina, Collins, Christopher E, Dervieux, Thierry, Kalunian, Kenneth C, Massarotti, Elena M, Narain, Sonali, O'Malley, Tyler, Putterman, Chaim, Ramsey-Goldman, Rosalind, Saxena, Amit, Wallace, Daniel J, Weinstein, Arthur   +12 more
core   +2 more sources